PD-L1 Negative NSCLC

Innovent’s IBI363 Shows Strong First-Line NSCLC Data

SAN FRANCISCO and SUZHOU, China, May 22, 2026 Innovent Biologics announced encouraging preliminary Proof-of-Concept (PoC) clinical data for IBI363,...

By cGxPwire Editor
May 23, 2026

We work Hard to get you posted with latest updates

Unwrap our new Directory

PD-L1 Negative NSCLC

Innovent’s IBI363 Shows Strong First-Line NSCLC Data